Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress
Cabaletta Bio, Inc. (CABA)
Company Research
Source: GlobeNewswire
– Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory patients; all three patients remained off immunomodulators since infusion and are off or tapering steroids as of the data cut-off – – CAR T cell expansion in all three patients without preconditioning was similar to expansion across 30+ patients dosed with preconditioning in the other RESET™ trials – – Initial dose data support continued exploration of rese-cel without preconditioning in pemphigus vulgaris at the current dose and evaluation of the no preconditioning regimen as an alternative treatment option in certain other autoimmune diseases – – All adult Phase 1/2 cohorts within the myositis, lupus, scleroderma and myasthenia gravis RESET trials are fully enrolled as of September 30, 2025 – PHILADELPHIA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and
Show less
Read more
Impact Snapshot
Event Time:
CABA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CABA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CABA alerts
High impacting Cabaletta Bio, Inc. news events
Weekly update
A roundup of the hottest topics
CABA
News
- Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Cabaletta Bio GAAP EPS of -$0.44 beats by $0.04 [Seeking Alpha]Seeking Alpha
- Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Cabaletta Bio (CABA): Assessing Valuation After Promising Clinical Trial Results and Growing Investor Interest [Yahoo! Finance]Yahoo! Finance
- Cabaletta Bio to Participate in Upcoming Investor Conferences in November and DecemberGlobeNewswire
CABA
Earnings
- 11/10/25 - Beat
CABA
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- CABA's page on the SEC website